Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Ripa

Showing results (41-50 of 59) with videos related to

Pageof 6
Sort By:
Expert Opinion on Pharmacotherapy|June 27, 2015
A multicenter, randomized, double-blind, placebo-controlled trial to assess the efficacy and safety of single-entity, once-daily hydrocodone tablets in patients with uncontrolled moderate to severe chronic low back painWarren Wen, Steve Sitar, Shau Yu Lynch, et al.
Spine|March 1, 1991
Series of ninety-two traumatic cervical spine injuries stabilized with anterior ASIF plate fusion techniqueD R Ripa, M G Kowall, P R Meyer, et al.
Postgraduate Medicine|December 9, 2016
Safety of buprenorphine transdermal system in the management of pain in older adultsJoseph V Pergolizzi, Robert B Raffa, Zachary Marcum, et al.
Giornale Di Clinica Medica|July 1, 1970
[Plasma renin in patients with congestive heart failure]R Ripa, R Alvisi, S Salzano, et al.
Journal of Pain Research|June 6, 2017
Use of immediate-release opioids as supplemental analgesia during management of moderate-to-severe chronic pain with buprenorphine transdermal systemSanford Silverman, Robert B Raffa, Marc J Cataldo, et al.
Expert Opinion on Pharmacotherapy|March 14, 2012
A randomized, 14-day, double-blind study evaluating conversion from hydrocodone/acetaminophen (Vicodin) to buprenorphine transdermal system 10 μg/h or 20 μg/h in patients with osteoarthritis painSteven R Ripa, Bill H McCarberg, Catherine Munera, et al.
Postgraduate Medicine|December 9, 2016
Effects of buprenorphine on QT intervals in healthy subjects: results of 2 randomized positive- and placebo-controlled trialsStephen C Harris, Joel Morganroth, Steven R Ripa, et al.
Giornale Di Clinica Medica|August 1, 1970
[Plasmatic renin in hepatopathic subjects]R Ripa, S Salzano, R Alvisi, et al.
Expert Opinion on Drug Safety|March 20, 2013
Application site adverse events associated with the buprenorphine transdermal system: a pooled analysisWarren Wen, Shau Yu Lynch, Catherine Munera, et al.
Journal of Pain and Symptom Management|September 28, 2011
Efficacy and safety of the seven-day buprenorphine transdermal system in opioid-naïve patients with moderate to severe chronic low back pain: an enriched, randomized, double-blind, placebo-controlled studyDeborah J Steiner, Steve Sitar, Warren Wen, et al.
Pageof 6

Showing results (41-50 of 59) with videos related to

Sort By:
Pageof 6
Expert Opinion on Pharmacotherapy|June 27, 2015
A multicenter, randomized, double-blind, placebo-controlled trial to assess the efficacy and safety of single-entity, once-daily hydrocodone tablets in patients with uncontrolled moderate to severe chronic low back painWarren Wen, Steve Sitar, Shau Yu Lynch, et al.
Spine|March 1, 1991
Series of ninety-two traumatic cervical spine injuries stabilized with anterior ASIF plate fusion techniqueD R Ripa, M G Kowall, P R Meyer, et al.
Postgraduate Medicine|December 9, 2016
Safety of buprenorphine transdermal system in the management of pain in older adultsJoseph V Pergolizzi, Robert B Raffa, Zachary Marcum, et al.
Giornale Di Clinica Medica|July 1, 1970
[Plasma renin in patients with congestive heart failure]R Ripa, R Alvisi, S Salzano, et al.
Journal of Pain Research|June 6, 2017
Use of immediate-release opioids as supplemental analgesia during management of moderate-to-severe chronic pain with buprenorphine transdermal systemSanford Silverman, Robert B Raffa, Marc J Cataldo, et al.
Expert Opinion on Pharmacotherapy|March 14, 2012
A randomized, 14-day, double-blind study evaluating conversion from hydrocodone/acetaminophen (Vicodin) to buprenorphine transdermal system 10 μg/h or 20 μg/h in patients with osteoarthritis painSteven R Ripa, Bill H McCarberg, Catherine Munera, et al.
Postgraduate Medicine|December 9, 2016
Effects of buprenorphine on QT intervals in healthy subjects: results of 2 randomized positive- and placebo-controlled trialsStephen C Harris, Joel Morganroth, Steven R Ripa, et al.
Giornale Di Clinica Medica|August 1, 1970
[Plasmatic renin in hepatopathic subjects]R Ripa, S Salzano, R Alvisi, et al.
Expert Opinion on Drug Safety|March 20, 2013
Application site adverse events associated with the buprenorphine transdermal system: a pooled analysisWarren Wen, Shau Yu Lynch, Catherine Munera, et al.
Journal of Pain and Symptom Management|September 28, 2011
Efficacy and safety of the seven-day buprenorphine transdermal system in opioid-naïve patients with moderate to severe chronic low back pain: an enriched, randomized, double-blind, placebo-controlled studyDeborah J Steiner, Steve Sitar, Warren Wen, et al.
Pageof 6